Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis
- 12 June 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 116 (3), 433-439
- https://doi.org/10.1007/s10549-009-0432-z
Abstract
To estimate the cumulative randomized evidence for the overall incidence of bisphosphonates induced jaw osteonecrosis in adjuvant treatment of breast cancer. Systematic review and meta-analysis of randomized clinical trials. Trials were located through PubMed, ISI, Cochrane Library, and major cancer scientific meetings searches. We identified 15 studies reporting data on osteonecrosis of the jaw. A total of 10,694 randomized women were included, of whom 5,312 received bisphosphonates and 5,382 received either placebo or no treatment. Osteonecrosis of the jaw was a rare event, occurring in 13 (0.24%) of the 5,312 patients receiving bisphosphonates, and in one of the 5,382 patients in the control group. All the 13 events of osteonecrosis of the jaw reported among bisphosphonates arms occur in patients undergoing treatment with zoledronic acid (13/3,987, 0.33%). No events of osteonecrosis of the jaw were reported among patients randomized to receive clodronate (n = 669), pamidronate (n = 460), risedronate (n = 171), and ibandronate (n = 25); however, these samples were too small to be able to rule out the condition. Treatment with zoledronic acid was significantly associated to the occurrence of osteonecrosis of the jaw (OR = 3.23, 95% CI = 1.7–8) compared with no use. No significant between-study heterogeneity was observed. Despite use of zoledronic acid is associated to a higher number of events compared with no use, the osteonecrosis of the jaw during the adjuvant treatment of breast cancer is a rare event. At current dosage, adjuvant use of bisphosphonates in breast cancer treatment is safe.Keywords
This publication has 29 references indexed in Scilit:
- Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast CancerClinical Cancer Research, 2008
- Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical TrialJournal of Clinical Oncology, 2008
- 2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let)European Journal of Cancer Supplements, 2007
- Antitumor Effects of Clinical Dosing Regimens of Bisphosphonates in Experimental Breast Cancer Bone MetastasisJNCI Journal of the National Cancer Institute, 2007
- Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2-Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230)Journal of Bone and Mineral Research, 2006
- Risk of Cancer Treatment—Associated Bone Loss and Fractures Among Women with Breast Cancer Receiving Aromatase InhibitorsClinical Breast Cancer, 2006
- Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survivalBritish Journal of Cancer, 2003
- Bisphosphonates induce apoptosis in human breast cancer cell linesBritish Journal of Cancer, 2000
- Endogenous Hormones and the Risk of Hip and Vertebral Fractures among Older WomenNew England Journal of Medicine, 1998
- Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.JCI Insight, 1996